A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Exclusion Criteria

• •Subject has a known hypersensitivity to any excipients of bimekizumab or adalimumab
• •Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections
• •Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
• •Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
• •Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
• •Subject has had previous exposure to adalimumab
• •Presence of active suicidal ideation or positive suicide behavior
• •Presence of moderately severe major depression or severe major depression
• •Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer